|
March
 Novavax
to sell $38mm equity offering
Praecis Pharma
in technology transfer with Gilead
Class action
brought against Northfield Labs  Medicis
strikes distribution deal for Reloxin 
BioMarin
to sell common stock and convertible debt
Curis
restates its financials; Delays 10-K
North
American Scientific gets Nasdaq delisting notice
Genentech
raises its earnings guidance Peregrine
Pharma adopts rights plan
Sunesis Pharma
announces $45mm PIPEs equity raise Hana Biosciences
licenses cancer drug candidates Fisher Scientific
buys Athena Diagnostics
Cerus
completes $39mm common stock offering
Titan
Pharma to sell $10mm of common stock
Cell
Genesys in $75mm equity line financing
Imclone
pays $32 mm tax penalty over former CEO
November
Biogen Idec
and Elan
get priority review for Tysabri Gilead
and Roche end Tamiflu dispute OSI
closes Eyetech,
after hesitating Serono
"explores its strategic alternatives" Momenta Pharma
adopts poison pill rights plan Friends
of Sam Waksal settle
insider trading charges
October Biogen IDEC
earnings disappoint Savient
restates additional financial statements
J&J
brings antitrust claim
against Amgen Barrier Therapeutics sued
CancerVax's
stock crashes over clinical results
Invitrogen
wins patent appeal against Stratagene
Lifecell
recalls product; Withdraws earnings guidance
Avalon
dual lists on
Archipelago Exchange
September
Cypress
Bioscience
stock crashes over
clinical results
Biogen
IDEC and Elan reapply for MS drug approval
One-third
of Transkaryotic
shares subject to appraisal
Biogen
IDEC sells plant
to Genentech
Ligand
restates financials: revenue recognition issues EpiCept
pulls IPO, even after cutting price in half ImmunoGen
renews Genentech agreement;
Stock
|
